<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04117347</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00161267</org_study_id>
    <secondary_id>1R61MH117157-01A1</secondary_id>
    <nct_id>NCT04117347</nct_id>
  </id_info>
  <brief_title>Morning Light Treatment for Traumatic Stress: The Role of Amygdala Reactivity</brief_title>
  <official_title>Morning Light Treatment for Traumatic Stress: The Role of Amygdala Reactivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of different amounts of time of morning
      light on brain emotional processing.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 24, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The outcomes assessor will be blinded to study arm. The PI, study coordinator and research assistants will remain unblinded to perform safety assessments and provide feedback on intervention adherence. Blinded staff will wear buttons as an upfront visual cue to remind participants not to talk about their treatment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in amygdala reactivity as measured by whole-brain oxygen-level dependent functional magnetic resonance imaging (fMRI) signal</measure>
    <time_frame>Baseline and treatment week 2 and treatment week 4</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Stress</condition>
  <arm_group>
    <arm_group_label>Light therapy A via the Re-Timer®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-15 minutes/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Light therapy B via the Re-Timer®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-30 minutes/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Light therapy C via the Re-Timer®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-60 minutes/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Light therapy A via the Re-Timer®</intervention_name>
    <description>Subjects will conduct light treatment in the mornings at home.</description>
    <arm_group_label>Light therapy A via the Re-Timer®</arm_group_label>
    <other_name>Re-Timer®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Light therapy B via the Re-Timer®</intervention_name>
    <description>Subjects will conduct light treatment in the mornings at home.</description>
    <arm_group_label>Light therapy B via the Re-Timer®</arm_group_label>
    <other_name>Re-Timer®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Light therapy C via the Re-Timer®</intervention_name>
    <description>Subjects will conduct light treatment in the mornings at home.</description>
    <arm_group_label>Light therapy C via the Re-Timer®</arm_group_label>
    <other_name>Re-Timer®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets criteria for traumatic stress

          -  Normal or corrected to normal vision

          -  Right-handed

          -  Fluency in English

          -  Physically able to travel for study visit attendance

        Exclusion Criteria:

          -  Significant chronic uncontrolled disease (e.g. uncontrolled diabetes, advanced liver
             disease, cancer, etc.)

          -  Severe hearing problem

          -  Intellectual disability or serious cognitive impairment

          -  Inability to tolerate enclosed spaces (e.g. the MRI machine)

          -  Ferrous-containing metals within the body

          -  Pregnant, trying to get pregnant, or breastfeeding

          -  Epilepsy

          -  Other research participation

          -  Frequent number of special events during study period (weddings, concerts, exams,
             etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen Burgess</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emily Spence</last_name>
    <phone>734-647-6657</phone>
    <email>morninglightstress@med.umich.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Helen Burgess, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 3, 2019</study_first_submitted>
  <study_first_submitted_qc>October 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 7, 2019</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Helen Burgess</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Circadian timing</keyword>
  <keyword>Mood</keyword>
  <keyword>Light</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The researchers are open to sharing data by any appropriate mechanism indicated by NIH program staff. That includes that identified research information will be entered into the National Institute of Mental Health's Database for Clinical Trials related to Mental Illness (NDCT)</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>After scientific papers are accepted for publication and the data will be available for 7 years after study completion.</ipd_time_frame>
    <ipd_access_criteria>Researchers requesting data will first have to sign a data sharing agreement, agreeing to the conditions of use governing access to the public release data, including restrictions against attempting to identify study participants, electronically securing the data while in use, destruction of the data after analyses are completed, reporting responsibilities, restrictions on redistribution of the data to third parties, no use of the data for commercial purposes and proper acknowledgement of the data resource.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

